Efavirenz Severe Hypersensitivity Reaction: Case Report and Rapid Desensitization Protocol Development

2012 ◽  
Vol 46 (5) ◽  
pp. 761-761 ◽  
Author(s):  
Hossein Khalili ◽  
Maryam Farasatinasab ◽  
Mahboobeh Hajiabdolbaghi
Keyword(s):  
Case Report ◽  
Hypersensitivity Reaction ◽  
Protocol Development ◽  
Desensitization Protocol ◽  
Severe Hypersensitivity Reaction

Successful desensitization of a patient with cetuximab hypersensitivity: A case report

2018 ◽  
Vol 25 (7) ◽  
pp. 1726-1730 ◽  
Author(s):  
Mohammad Solduzian ◽  
Saeed Anvari ◽  
Hamidreza Taghvaye Masoumi ◽  
Farhad Shahi ◽  
Zahra Jahangard-Rafsanjani
Keyword(s):  
Colorectal Cancer ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Hypersensitivity Reaction ◽  
Drug Discontinuation ◽  
Hypersensitivity Reactions ◽  
Case Description ◽  
Treatment Team ◽  
Desensitization Protocol ◽  
Severe Hypersensitivity Reaction

Background Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management. Case description A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol. Conclusions This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.

scholarly journals Severe hypersensitivity reaction to etoposide phosphate: A case report

2020 ◽  
Vol 8 (9) ◽  
pp. 1821-1823 ◽  
Author(s):  
Camille Cotteret ◽  
Julia Rousseau ◽  
Kaouther Zribi ◽  
Joel Schlatter
Keyword(s):  
Case Report ◽  
Hypersensitivity Reaction ◽  
Etoposide Phosphate ◽  
Severe Hypersensitivity Reaction

Graded Dalbavancin Challenge in a Patient With Severe Vancomycin Hypersensitivity Reaction

2019 ◽  
Author(s):  
Kelly T Ishizuka ◽  
Thao K Tran ◽  
Andrew G Ayars ◽  
Alice S Chau ◽  
Jeannie D Chan
Keyword(s):  
Case Report ◽  
Hypersensitivity Reaction ◽  
Cross Reactivity ◽  
Chemical Structures ◽  
Similar Chemical ◽  
Graded Challenge ◽  
Severe Hypersensitivity Reaction

Abstract Cross-reactivity should be considered when treating patients with a previous hypersensitivity reaction within the same class of antibiotics that share similar chemical structures. This case report describes a patient with severe hypersensitivity reaction to vancomycin who successfully tolerated a dalbavancin graded challenge.

scholarly journals Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report

2021 ◽  
pp. 379-383
Author(s):  
Meghan L. McPhie ◽  
Kevin Y.M. Ren ◽  
J. Michael Hendry ◽  
Sonja Molin ◽  
Thomas Herzinger
Keyword(s):  
Case Report ◽  
Hepatitis C ◽  
Adverse Effects ◽  
Hypersensitivity Reaction ◽  
Allergic Reaction ◽  
Delayed Type Hypersensitivity ◽  
Histological Features

Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with the initiation of ledipasvir/sofosbuvir treatment for his hepatitis C. Clinical and histological features were consistent with a delayed-type hypersensitivity reaction to red ink.

Sign in / Sign up

Export Citation Format

Share Document